"I treat pancreatic cancer and only 1% of those patients respond and the rest don't," says Osama Rahma, principal investigator at the Center for Immuno-Oncology and Gastroenterology Cancer Center at Dana-Farber Cancer Institute. Rahma discusses his research in cancer immunotherapy and his development of novel immunotherapy drugs.